Overview of possible relation of defects in purine metabolism to immune deficiency.
D000225:Adenine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000633:toxicity; D000243:Adenosine Deaminase / Q000172:deficiency; D058892:Adenosine Deaminase Inhibitors; D000818:Animals; D002478:Cells, Cultured; D003070:Coformycin / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000201:enzymology* / Q000378:metabolism / Q000628:therapy; D007166:Immunosuppressive Agents / Q000494:pharmacology; D015649:Pentostatin; D011684:Purine Nucleosides / Q000378:metabolism; D011683:Purine-Nucleoside Phosphorylase / Q000172:deficiency; D011686:Purine-Pyrimidine Metabolism, Inborn Errors / Q000201:enzymology* / Q000378:metabolism / Q000628:therapy
D058892:Adenosine Deaminase Inhibitors; D007166:Immunosuppressive Agents; D011684:Purine Nucleosides; D003070:Coformycin; D015649:Pentostatin; C010192:9-(2-hydroxy-3-nonyl)adenine; D011683:Purine-Nucleoside Phosphorylase; D000243:Adenosine Deaminase; D000225:Adenine